Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00484328
Status:
COMPLETED
Last Update Posted:
2018-01-09
First Post:
2007-06-07
Brief Title:
Ribavirin Its Dosing Regime
Sponsor:
Maastricht University Medical Center
Organization:
Maastricht University Medical Center
Study Overview
Official Title:
Ribavirin Its Dosing Regime
Status:
COMPLETED
Status Verified Date:
2011-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Ribados
Brief Summary:
The purpose of this study is to determine if the medicines for chronic hepatitis C can be taken once daily instead of twice daily
Detailed Description:
The standard treatment of patients with chronic hepatitis C infection HCV is treatment with ribavirin Actually the compliance 2x daily seems to be a problem To increase patients compliance it is investigated if the total dose of ribavirin can be taken once daily
The pharmacokinetics of ribavirin at different dosage regimes is investigated
The pharmacokinetics of ribavirin at different dosage regimes is investigated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None